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Actions of the antihistaminergic clemastine
on presymptomatic SOD1-G93A mice
ameliorate ALS disease progression
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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a disease with a strong neuroinflammatory component
sustained by activated microglia contributing to motoneuron death. However, how to successfully balance
neuroprotective versus neurotoxic actions by the use of antinflammatory agents is still under scrutiny. We have
recently shown that the antihistamine clemastine, an FDA-approved drug, can influence the M1/M2 switch
occurring in SOD1-G93A ALS microglia.
Methods: Here, we have chronically treated female SOD1-G93A mice with clemastine, evaluated disease
progression and performed mice lumbar spinal cord analysis at symptomatic and end stage of the disease.
Moreover, we have studied the mechanism of action of clemastine in primary adult spinal SOD1-G93A microglia
cultures and in NSC-G93A motor neuron-like cells.
Results: We found that a short treatment with clemastine (50 mg/kg) from asymptomatic (postnatal day 40) to
symptomatic phase (postnatal day 120) significantly delayed disease onset and extended the survival of SOD1-G93A
mice by about 10 %. Under these conditions, clemastine induced protection of motor neurons, modulation of
inflammatory parameters, reduction of SOD1 protein levels and SQSTM1/p62 autophagic marker, when analysed
immediately at the end of the treatment (postnatal day 120). A long treatment with clemastine (from asymptomatic
until the end stage) instead failed to ameliorate ALS disease progression. At the end stage of the disease, we found
that clemastine short treatment decreased microgliosis and SOD1 protein and increased LC3-II autophagic marker,
while the long treatment produced opposite effects. Finally, in spinal microglia cultures from symptomatic
SOD1-G93A mice clemastine activated inflammatory parameters, stimulated autophagic flux via the mTOR signalling
pathway and decreased SOD1 levels. Modulation of autophagy was also demonstrated in NSC34 SOD1-G93A motor
neuron-like cells.
Conclusions: By gaining insights into the ameliorating actions of an antihistaminergic compound in ALS disease,
our findings might represent an exploitable therapeutic approach for familial forms of ALS.
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Background
Amyotrophic lateral sclerosis (ALS) is a neurodegenera-
tive disease characterised by selective loss of upper and
lower motor neurons and with a marked multifactorial
nature where genetic factors and dysregulation of crucial
molecular pathways contribute to disease pathogenesis
[1]. Approximately 10 % of cases can be attributed to a
familial form, and one of the best characterised forms of
familial ALS is caused by mutations in the gene encod-
ing for superoxide dismutase 1 (SOD1) and occurring in
about 15–20 % of familial patients. Mutated SOD1 gene
can acquire both gain and loss of function deleterious
mutations that modify SOD1 activity, leading to the ac-
cumulation of highly toxic intracellular aggregates and
becoming one of the mechanisms sustaining ALS aetio-
pathogenesis together with the well-known neuroinflam-
mation [1–4].
Emerging evidence has recently suggested the occur-
rence of the main degradative mechanism of misfolded
proteins, autophagy [5], in the pathogenesis of ALS [6].
Altered macroautophagy is reported in the spinal cord of
SOD1 mutant mice [7] and autophagy overexpression is
proved in motor neurons of ALS mice by in vivo optical
imaging [8]; moreover, inefficient autophagosome-
lysosome fusion is reported in ALS patients [9, 10] to the
point that a strategy in modulating autophagic flux may
have a promise in ALS treatment [11, 12]. The p62/
sequestosome 1 protein has been identified as a compo-
nent of pathological protein inclusions in neurodegenera-
tive diseases including ALS, besides being implicated in
autophagy as an adaptor protein that acts as a bridge
between aggregates and autophagy clearance [13]. Although
autophagy constitutes a physiological mechanism to degrade
proteins that is generally beneficial for cells, if uncontrolled,
it may be extremely harmful for neuronal survival [6].
The histaminergic system is involved in numerous ac-
tions, comprising sensory and motor functions, and
histamine-related drugs have been lately recognised to
have a therapeutic role in CNS pathologies [14]. For in-
stance, histamine H3 receptor antagonism inhibits
mTOR phosphorylation and reinforces autophagy, thus
protecting against ischaemic injury [15]. Latrepirdine, an
antihistamine that regulates the metabolism of the
amyloid-β/A4 precursor protein and autophagy, amelio-
rates disease pathology in an Alzheimer mouse model
[16]. Moreover, latrepirdine reduces γ-synuclein protein
aggregates in vivo, slowing progression of proteinopathy
in γ-synuclein transgenic mice [17]. Recently, latrepir-
dine administered until symptomatic phase was shown
to increase life span in SOD1-G93A mice by activating
the autophagy-related adenosine 5′-monophosphate-ac-
tivated protein kinase [18].
Clemastine (Tavegil™), an antihistamine drug originally
marketed for the treatment of allergic rhinitis, is currently
on phase II clinical trial for patients with relapsing forms
of multiple sclerosis (www.clinicaltrial.gov), due to its
recently discovered remyelinating properties [19, 20]. We
have recently identified clemastine as a compound also
capable of counteracting spinal cord pathology and
neuroinflammatory responses in the SOD1-G93A mouse
model of ALS, however not affecting mice survival, when
administrated at 10 mg/kg from pre-symptomatic to the
end stage of the disease [21].
Here we have administrated a higher dose of clemastine
(50 mg/kg) in SOD1-G93A mice under two regimens, one
up to symptoms onset and one up to the end stage of the
disease. Moreover, we have dissected the actions of clem-
astine in SOD1-G93A lumbar spinal cord tissues, primary
adult SOD1-G93A microglia and motor neuron like cul-
tures, in order to investigate its pharmacological potential
in perturbing ALS pathogenesis.
Methods
Reagents
Bafilomycin - A1, clemastine, wortmannin and all re-




Adult B6.Cg-Tg(SOD1-G93A)1Gur/J mice expressing
high copy number of mutant human SOD1 with a G93A
substitution (SOD1-G93A) were originally obtained from
Jackson Laboratories (USA) and bred in our indoor ani-
mal facility. Transgenic hemizygous SOD1-G93A males
were crossbred with C57BL/6 females, both maintained
on the C57BL/6 genetic background.
Because there is gender difference in the SOD1-G93A
mice response to pharmacological treatments [22], we
decided to use only females, in order to avoid gender
diversity. Animals were housed at constant temperature
(22 ± 1 °C) and relative humidity (50 %) with a regular
12-h light cycle (light 7 am–7 pm) throughout the ex-
periments. Food and water were freely available. When
animals reached the score of 3.5 (see below), macerated
food was given daily for easy access to nutrition and hy-
dration. All animal procedures were performed accord-
ing to the European Guidelines for the use of animals in
research (2010/63/EU) and the requirements of Italian
laws (D.L. 26/2014). The ethical procedure was approved
by the Animal Welfare Office, Department of Public
Health and Veterinary, Nutrition and Food Safety,
General Management of Animal Care and Veterinary
Drugs of the Italian Ministry of Health (protocol number
167/2013B). All efforts were made to minimise animal
suffering and the number of animals necessary to produce
reliable results. Transgenic progeny were genotyped by
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analysing tissue extracts from tail tips, as previously
described [23].
Pharmacological treatments with clemastine and analysis
of disease progression
We administered clemastine at a concentration of
50 mg/kg body weight dissolved in 30 % sulfobutylether-
β-cyclodextrin (SBE) for five times a week by intraperito-
neal injection starting from postnatal day 40 (a time that
provided promising results with a lower dose of 10 mg/
kg) until either the end stage or postnatal day 120. Ve-
hicle groups received 30 % SBE. SBE is a chemically
modified cyclodextrin with a structure designed to
optimise the solubility and stability of drugs. To de-
termine disease onset and neuromuscular function,
mice were subjected to grip test twice a week, start-
ing at 70 days of age. Briefly, the following hanging
wire test was used for the grip test: the mouse was
placed on a wire grid (wire thickness, 2 mm) that
was gently shaken to prompt the mouse to hold onto
the wire and the grid was then turned upside down.
The latency for the mouse to release the grid was re-
corded within three attempts for an arbitrary max-
imum of 90 s [24]. If a mouse dropped from the grid
within 90 s in three consecutive trials, it was defined
as symptomatic. Behavioural scores and body weights
were assessed two times a week beginning at 40 days
of age, in order to monitor disease progression. Behav-
ioural score employed a rating scale from 5 (healthy with-
out any symptom of paralysis) to 1 (fully paralysis of the
hind limbs, animals predominantly lie on the side, and are
not able to straighten up within 30 s, after turning them
on the back) according to Apolloni et al. [21]. After
reaching a score of 1, the animals were euthanized, ac-
cording to the guidelines for preclinical testing and colony
management [25].
Adult spinal cord microglia cultures
Adult primary microglia from spinal cord were prepared
from symptomatic, i.e. postnatal day 120 SOD1-G93A
female mice. Briefly, mice were euthanized by CO2 as-
phyxiation and lumbar spinal cords were taken and sub-
merged in a Petri dish containing ice-cold HBSS. After
removing the meninges, the spinal cords were minced
and digested with trypsin (2.5 g/L irradiated porcine
trypsin and 0.2 g/L EDTA in HBSS) and incubated at
37 °C for 30 min. After dissociation and passage through
40-μm filter, cells were then plated in 35-mm poly-D-
lysine coated plates. After 4 h, non-adherent cells were
washed off. We obtained a population of ≥98 % microglia
enriched in CD11b immunoreactivity and negative for
astrocyte-GFAP marker.
Mouse motor neuron cell line NSC34 SOD1-G93A
Construction of NSC34 cells stably transfected with
mutant human SOD1-G93A DNA was described else-
where [26]. Cells were grown in DMEM/F12 medium
supplemented with 10 % FBS (Invitrogen, USA). Induc-
tion of SOD1-G93A gene was obtained by adding 1 μg/
ml doxycycline to the culture medium for 48 h and veri-
fied by western blot with anti-SOD1 antibody.
Western blot analysis
A section of lumbar spinal cord tissue was collected and
homogenised in Triton X-100 containing protease
inhibitor cocktail (Sigma-Aldrich) by sonication. Cell
cultures were harvested in SDS Laemmli sample buffer.
Separation of protein components was performed by
Mini-PROTEAN® TGX™ Gels (BioRad, USA), followed
by transfer onto nitrocellulose membranes (Amersham
Biosciences, Italy). After saturation with 5 % non-fat dry
milk, blots were probed overnight at 4 °C with the spe-
cific primary antibodies: rabbit anti-ARG1 (1:1000, Milli-
pore, USA), rat anti-CD68 (1:500, AbD Serotech, UK),
rabbit anti-CD163 (1:100, Santa Cruz Biotechnology,
USA), rabbit anti-Iba1 (1:1000, Wako, USA), rabbit anti-
LC3B (1:1000, Cell Signaling Technology Inc, USA), rabbit
anti-mTOR and phospho-mTOR (1:1000, Cell Signaling
Technology Inc), rabbit anti-nuclear factor-kappa B (NF-
kB) (1:500, Cell Signaling Technology Inc), rabbit anti-
P2X4 (1:500, Alomone Labs, Israel), rabbit anti-P2X7
(1:500, Alomone Labs), rabbit anti-P2Y12 (1:200, Anaspec,
USA), anti-p44/42 MAPK (ERK1/2) (L34F12) mouse anti-
body (1:1000) and anti-phospho-p44/42 MAPK (ERK1/2)
(Thr202/Tyr204) (1:1000, Cell Signaling Technology Inc.),
rabbit anti-SOD1 (1:1000, Enzo Life sciences, USA),
mouse anti-SQSTM1/p62 (1:1000, Abcam, USA). After in-
cubation for 1 h with a specific HRP-conjugated second-
ary antibody, blots were visualised using ECL Advance
Western blot detection kit (Amersham Biosciences). Sig-
nal intensity quantification was performed by Kodak
Image Station analysis software. Values were normalised
with mouse anti-GAPDH (1:2500, Calbiochem, USA).
Immunofluorescence and confocal microscopy
Mice were anaesthetized by intraperitoneal injection
with chloral hydrate (500 mg/kg) and were perfused
intracardially with 50 ml of PBS, followed by 4 %
paraformaldehyde (PFA) at pH 7.4. Immunofluorescence
analysis was performed as described [21]. Spinal cord
sections were incubated with mouse monoclonal anti-
Neuronal Nuclei (NeuN) (1:200, Millipore). SOD1-G93A
primary microglia were fixed for 20 min in 4 % PFA,
permeabilized for 5 min in PBS containing 0.1 % Triton
X-100. The cells were then incubated overnight at 4 °C
in 1 % BSA in PBS with rabbit anti-ARG-1 (1:200),
mouse anti-CD68 (1:100, Santa Cruz), rat anti-CD11b
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(1:200,Wako), rabbit anti-CD163 (1:30), mouse anti-glial
fibrillary acidic protein (GFAP) (1:10, AbD Serotech),
rabbit anti-P2Y12 (1:50), rabbit anti-SOD1(1:400), rabbit
anti-LC3B (1:400) and mouse monoclonal anti-NeuN
(1:200). The cultures were stained for 3 h with appropriate
secondary antibodies. Nuclei were stained with 1 μg/ml
Höechst 33258 for 5 min, and the cells were finally
mounted and coverslipped with gel/mount anti-fading
(Biomeda, USA). Immunofluorescence was analysed by
means of a confocal laser scanning microscope (Zeiss,
LSM700, Germany), using always identical acquisition pa-
rameters (laser intensity, photomultiplier gain, pinhole
aperture, electronic zoom) for all the images. The bright-
ness and contrast of the digital images were adjusted using
the Zen software.
Nissl staining
Mice were anaesthetized by intraperitoneal injection
with chloral hydrate (500 mg/kg) and were perfused in-
tracardially with 50 ml of PBS, followed by 4 % PFA at
pH 7.4. Serial spinal cord sections (n = 12) from L3–L5
were randomly selected and after hydration stained with
1 % cresyl violet. Stained sections were dehydrated grad-
ually in 50–100 % alcohol, cleared in xylene, and cover-
slipped with Eukitt (Sigma-Aldrich). The whole ventral
horn of the spinal cord was photographed at ×20 magni-
fication with Zeiss Axioskop 2 microscope. Polygonal-
shaped neurons larger than 20 μm, with a well-defined
cytoplasm with nucleus and nucleolus [27] were then
counted using Neurolucida software (MBF Bioscience,
USA).
Statistical analysis
Data are presented as mean ± standard error of the means
(SEM). Analysis was performed with the statistical soft-
ware package MedCalc (Medcalc Software, Belgium).
Mice survival was analysed with the Kaplan-Meier Graph
followed by log-rank statistics. Analysis of data was per-
formed using ANOVA. Statistical differences between
groups were verified by Student’s t test. *p < 0.05 was con-
sidered significant.
Results
Clemastine short treatment prolongs survival in
SOD1-G93A mice
In order to improve the potential of clemastine in ameli-
orating ALS disease progression, we performed two
different treatments with a high dose of clemastine
(50 mg/kg) in SOD1-G93A mice, both starting at
postnatal day 40 (PND) but ending at either PND 120
(short treatment) or the end stage of the disease (long
treatment) (Fig. 1a).
As shown in Fig. 1b, both clemastine short and long
treatment provided a delay of 8 days in disease onset
with respect to vehicle mice (128 days in short treat-
ment, 127 days in long treatment vs 120 days in vehicle),
as established by hanging grip test.
Conversely, only clemastine short treatment (red
line) ameliorated body weight (Fig. 1c) and behav-
ioural scores (Fig. 1d) until the late phases of disease.
Moreover, it increased the time to reach stages of
moderate deterioration, as evaluated by measuring the
impairment in the hanging grip test of 25 % (128 days
for vehicle vs 139 days for clemastine, Fig. 1e) and of
50 % (131 days for vehicle vs 142 days for clemastine,
Fig. 1f ). Finally, clemastine short treatment (red line)
significantly improved survival by 16 days (~10 %)
with respect to the vehicle mice (Fig. 1g). When
clemastine was instead administrated in SOD1-G93A
mice up to the end stage (long treatment, blue line),
it failed to affect disease progression (Fig. 1c) and
survival (Fig. 1g).
Clemastine short treatment affects inflammatory markers
and protects motor neurons in the lumbar spinal cord of
SOD1-G93A mice at symptomatic phase
In order to investigate the beneficial effects of clemastine
short treatment in SOD1-G93A mice, we analysed lum-
bar spinal cord tissues at PND 120 (Fig. 2a). To examine
motoneuron survival, we performed Nissl staining in
L3–L5 spinal cord (Fig. 2b). A significant reduction of
motoneuron number occurred in vehicle SOD1-G93A
mice as compared to wild type (WT), and this was in
part prevented by clemastine (respect to WT mice:
motor neurons surviving in vehicle = 40.3 ± 3 %, in clem-
astine = 64.6 ± 5.3 %, Fig. 2b). The neuroprotective effects
exerted by clemastine were further confirmed by NeuN
immunofluorescence (Fig. 2c).
By analysing microglia/macrophage related markers,
we proved that the protein levels of Iba1 and CD68,
together with arginase-1 (ARG-1) and CD163 markers,
were increased in clemastine-treated SOD1-G93A respect
to vehicle mice (respect to WT mice; for Iba1, vehicle-
treated mice = 5 ± 2; clemastine-treated mice = 13 ± 3.9;
for CD68, vehicle-treated mice = 3.8 ± 0.7; clemastine-
treated mice = 12 ± 2; for ARG-1, vehicle-treated mice
= 1.2 ± 0.3; clemastine-treated mice = 2.5 ± 0.8; for
CD163, vehicle-treated mice = 1.3 ± 0.3; clemastine-
treated mice = 3 ± 0.7, Fig. 2d).
Finally, given the recognised role of purinergic signal-
ling in ALS neuroinflammatory processes [28], we dem-
onstrated that the protein levels of purinergic receptors
P2X7 (2.9 ± 0.3 compared to vehicle-treated mice) and
P2Y12 (5.2 ± 1 compared to vehicle-treated mice) were
significantly increased by clemastine, while not statisti-
cally significant effect was observed for P2X4 protein
content (Fig. 2e).
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Fig. 1 Clemastine treatment up to postnatal day 120 prolongs survival in SOD1-G93A mice. a Schematic representation of experimental in vivo
design. b Short and long clemastine treatments delay disease onset of SOD1-G93A mice by 8 days (128 days for short treatment, 127 days for
long treatment vs 120 days for vehicle) (p≤ 0.05). c Body weight and d behavioural scores are improved in clemastine short treatment (red line),
but not in long treatment (blue line), with respect to vehicle mice (black line) (*p≤ 0.05). WT mice (green line). Short clemastine-treated mice show
a significant difference in the time to reach a 25 % (e) and a 50 % (f) grip strength impairment, with respect to vehicle-treated SOD1-G93A mice
(p < 0.05). g Short clemastine-treated mice (red line) show a significant difference in median survival, with respect to vehicle-treated SOD1-G93A
mice, as shown by Kaplan–Meier survival curves (186 days for clemastine vs 170 days for vehicle; p < 0.05). Long clemastine-treated mice (blue line)
show no significant differences in median survival with respect to vehicle-treated SOD1-G93A mice, as shown by Kaplan–Meier survival curves
(160 days for clemastine vs 160 days for vehicle). WT group, n = 6 mice; vehicle- and long clemastine-treated groups, n = 12 mice/group; short
clemastine-treated, n = 6 mice
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Fig. 2 Clemastine short treatment affects the spinal cord pathology in SOD1-G93A mice at symptomatic phase of the disease. a Schematic
representation of experimental design. b Spinal cord sections (L3–L5) from WT (~120 days) and vehicle- or clemastine-treated SOD1-G93A mice
at PND 120 (n = 4/group) are stained with cresyl violet (scale bar 100 μm) and assessment of motoneuron number is performed by percentage
quantification (n = 4/group) (t test referred to WT *p < 0.05 or to vehicle-SOD1-G93A, # p < 0.05). c Spinal cord sections of vehicle- or clemastine-
treated SOD1-G93A mice at PND 120 were then stained with anti-NeuN (scale bar = 40 μm). d Equal amounts of total lumbar spinal cord lysates
from WT mice (~120 days) and vehicle- or clemastine-treated SOD1-G93A mice at PND 120 (n = 3/group) are subjected to western blotting with
anti-Iba1, anti-CD68, anti-ARG-1, anti-CD163 and anti-GAPDH for protein normalisation. Data represent mean ± S.E.M. Statistical significance is
calculated by student’s t test referred to WT, * p < 0.05, or to vehicle SOD1-G93A mice, #p < 0.05. e Equal amounts of lumbar spinal cord lysates
from vehicle- or clemastine-treated SOD1-G93A mice at PND 120 (n = 3/group) are subjected to western blotting with anti-P2X7, anti-P2X4,
anti-P2Y12 and anti-GAPDH. Data represent mean ± S.E.M. Statistical significance was calculated by student’s t test, as referred to vehicle-treated
SOD1-G93A mice, * p < 0.05
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Clemastine short treatment decreases SOD1 and SQSTM1/
p62 levels in SOD1-G93A mice at symptomatic phase
Strategies that limit the toxic SOD1 protein aggrega-
tion may have therapeutic potential by accelerating
SOD1 degradation [11]. For this reason, we asked if
clemastine might also work by reducing the levels of
SOD1 protein. In clemastine-treated mice, high mo-
lecular weight SOD1 aggregates were almost undetect-
able (Fig. 3a) and clemastine was able to significantly
decrease the level of monomeric SOD1 protein in lumbar
spinal cord of SOD1-G93A mice respect to vehicle
(Fig. 3b).
Since antihistamines are lately emerging as autophagy
modulators, we analysed the level of the autophagic
marker microtubule-associated protein 1 light chain 3-II
(LC3-II), the lipidated form of LC3-I, which is aug-
mented in SOD1-G93A respect to WT mice [29]. Con-
firming this result (Fig. 3c), we moreover showed that
clemastine slightly increased LC3-II protein level respect
to SOD1-G93A vehicle mice (respect to WT, 2.2 ± 0.1 in
vehicle-treated mice and 2.7 ± 0.5 in clemastine-treated
mice, p > 0.05, Fig. 3c). Since it is known that SQSTM1/
p62 autophagy substrate accumulates in the lumbar






























































Fig. 3 Effects of clemastine short treatment on SOD1 and SQSTM1/p62 protein levels in symptomatic SOD1-G93A mice. a Representative images
of total lumbar spinal cord lysates from vehicle- and clemastine- treated SOD1-G93A mice at PND 120 subjected to western blotting under
non-reducing conditions with anti-SOD1 and anti-GAPDH for protein normalisation. b Quantitative analysis of mutant SOD1 monomer band
density in mice lumbar spinal cords. Data represent mean ± S.E.M. Statistical significance was calculated by student’s t test, as referred to vehicle-
treated SOD1-G93A mice, * p < 0.05. c Equal amounts of total lumbar spinal cord lysates from WT mice (~120 days) and vehicle- or clemastine-treated
SOD1-G93A mice (n = 4/group) are subjected to western blotting with anti LC3-I/II or in d with anti-SQSTM1/p62. Anti-GAPDH is used for protein
normalisation. Data represent mean ± S.E.M. Statistical significance was calculated by student’s t test, as referred to WT, or to vehicle-treated
SOD1-G93A mice, * p < 0.05
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measured the level of SQSTM1/p62 protein and demon-
strated that it was significantly down-regulated in
clemastine-treated mice respect to vehicle (6.8 ± 1.3 in
vehicle-treated mice and 3.8 ± 1.2 in clemastine-treated
mice, respect to WT, Fig. 3d).
Comparison between clemastine short and long
treatment on SOD1, LC3-II, CD68 and NF-kB expression in
SOD1-G93A mice spinal cord at the end stage of the
disease
In order to investigate if the effects of clemastine short
treatment were maintained up to late phases of ALS
disease, we finally analysed lumbar spinal cord tissues at
the end stage of the disease (Fig. 4a). Clemastine short
treatment markedly diminished SOD1 levels with re-
spect to vehicle-treated mice (for SOD1 monomer, 1 ±
0.2 in vehicle vs 0.4 ± 0.04 in clemastine, for SOD1 high
molecular weight bands 1 ± 0.1 in vehicle vs 0.4 ± 0.1 in
clemastine, Fig. 4b). Concomitantly, the level of LC3-II
resulted significantly increased in the same spinal cord
tissue (1 ± 0.5 in vehicle vs 2.91 ± 0.8 in clemastine,
Fig. 4c). Moreover, clemastine decreased CD68 protein
level with respect to vehicle group, although not signifi-
cantly (1 ± 0.5 in vehicle vs 0.6 ± 0.1 in clemastine,
Fig. 4d, p > 0.05). Since a master regulator of inflamma-
tion, NF-kB that triggers microglia-induced motoneuron
death in ALS, is known to be up-regulated in SOD1-
G93A mice spinal cord [31], we next analysed its level in
clemastine-treated mice. As shown in Fig. 4e, clemastine
decreased NF-kB protein expression with respect to
vehicle-treated mice (1 ± 0.2 in vehicle vs 0.57 ± 0.1 in
clemastine, p > 0.05).
Finally, to dissect the differences occurring between
clemastine short and long treatment, we next analysed
the lumbar spinal cord of clemastine long-treated mice
at the end stage of the disease (Fig. 4f ). We demon-
strated that clemastine long treatment significantly aug-
mented SOD1 protein levels compared to vehicle (1 ±
0.2 in vehicle vs 3 ± 0.7 in clemastine, for SOD1 mono-
mer; 1 ± 0.1 in vehicle vs 4.3 ± 0.6 in clemastine for
SOD1 high molecular weight bands, Fig. 4g), while LC3-
II levels were not up-regulated in the clemastine group
(1 ± 0.1 in vehicle vs 0.6 ± 0.2 in clemastine, p > 0.05,
Fig. 4h), differently from what observed with clemastine
short treatment. Moreover, clemastine significantly up-
regulated CD68 (1 ± 0.2 in vehicle vs 3.6 ± 0.4 in clemas-
tine, Fig. 4i) and NF-kB (1 ± 0.3 in vehicle vs 2.4 ± 0.7 in
clemastine, Fig. 4j) with respect to vehicle-treated mice.
In primary spinal microglia from symptomatic
SOD1-G93A mice, clemastine modulates inflammation
and induces autophagy
Since inflammatory configuration of ALS microglia is
regionally and temporally specific [32], in order to dissect
the clemastine actions mediated by microglia, we used
spinal cord microglia purified from SOD1-G93A mice at
PND 120. We proved that 30-μM clemastine for 6 h mod-
ulated inflammatory features by increasing the protein
expression of CD68 (5.9 ± 0.1 fold vs control) and M2-like
markers arginase-1 (5.5 ± 2 fold vs control) and CD163
(6.8 ± 1 fold vs control), as well as P2X7 (1.5 ± 0.2 fold vs
control) and P2Y12 (1.4 ± 0.2 fold vs control), while de-
creased P2X4 levels by about 70 % compared to unstimu-
lated microglia (Fig. 5a). By double immunofluorescence
and confocal analysis with anti-CD11b (microglia marker,
red) and respectively anti-CD68 (green), anti-ARG-1
(green), anti-CD163 (green) or anti-P2Y12 (green) anti-
bodies (Fig. 5b-e), we finally confirmed the up-regulation
of CD68, arginase-1, CD163 and P2Y12 levels.
We next studied the effect of clemastine on SOD1
level by proving that clemastine at 30 μM for 6 h reduced
SOD1 protein of about 50 % respect to control SOD1-
G93A microglia (Fig. 6a). By double immunofluorescence
with CD11b (red) and SOD1 (green) antibodies, we dem-
onstrated a reduced SOD1 staining intensity in clemastine-
treated microglia compared to control (Fig. 6b).
By analysing autophagy marker, we then proved that
the level of SQSTM1/p62 was significantly reduced by
clemastine of about 30 % with respect to control cells
(Fig. 6c). We next examined the signalling pathway of
mTOR, a key regulator of autophagy that can be moni-
tored by the levels of phosphorylated-mTOR (p-mTOR)
[33]. We observed a significant reduction of p-mTOR in
clemastine-treated cells with respect to control, suggest-
ing enhanced autophagic activity in SOD1-G93A micro-
glia via inhibition of the mTOR signalling pathway
(Fig. 6d).
A correct way to define if a treatment augments a true
autophagic flux (instead of non-productive late stage au-
tophagy) is to determine LC3-I to LC3-II conversion in the
presence of the vacuolar ATPase inhibitor bafilomycin-A1
[33]. Indeed, we demonstrated that clemastine per se in-
creases LC3-II by 5 ± 1.6-fold respect to control cells, while
the addition of bafilomycin-A1 further increased LC3-II by
16.9 ± 2.5-fold, consistently with an accelerated true
autophagic flux (Fig. 6e). This was also demonstrated by
immunofluorescence with anti-LC3B antibody (red), where
LC3B-positive dots were indeed augmented in SOD1-
G93A microglia in the presence of bafilomycin A-1 and
clemastine respect to clemastine alone (Fig. 6f).
To determine if the decrease in mutant SOD1 by
clemastine could be due to enhanced autophagy, we
treated microglia with the phosphoinositide 3-kinase
inhibitor wortmannin, known to block an early stage of
autophagy [33]. As shown in Fig. 6g, in the presence of
wortmannin, clemastine failed to decrease SOD1 levels.
Finally, since increased autophagy can contribute to
microglia activation [34], we measured CD68 protein
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Type of treatment Start End Duration Major End-point
Clemastine 
short treatment
40 days 120 days 80 days tissue analysis at
end stage
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Fig. 4 Short and long clemastine treatments differently modulate SOD1, LC3-II, CD68 and NF-kB in SOD1-G93A mice spinal cord at the end stage.
a Schematic representation of experimental design. b Equal amounts of the total lumbar spinal cord lysates from vehicle and short clemastine-
treated SOD1-G93A mice at the end stage (n = 4/group) are subjected to western blotting with anti-SOD1 under non-reducing conditions
(right panel shows the monomer band and left panel shows the high molecular weight bands). Anti-GAPDH is used for protein normalisation.
c Equal amounts of total lumbar spinal cord lysates from vehicle and short clemastine-treated SOD1-G93A mice at the end stage (n = 4/group)
are subjected to western blotting with anti-LC3-I/II or in d with anti-CD68 or in e with anti-NF-kB. Anti-GAPDH is used for protein normalisation.
Data represent mean ± S.E.M. Statistical significance is calculated by student’s t test referred to vehicle SOD1-G93A mice, * p < 0.05. f Schematic
representation of experimental design. g Equal amounts of total lumbar spinal cord lysates from vehicle- and long clemastine-treated SOD1-G93A
mice at the end stage (n = 4/group) are subjected to western blotting with anti-SOD1 under non-reducing conditions (right panel shows the
monomer band and left panel shows the high molecular weight bands). h Equal amounts of total lumbar spinal cord lysates from vehicle- and
long clemastine-treated SOD1-G93A mice at the end stage (n = 4/group) are subjected to western blotting with anti-LC3-I/II or in i with anti-CD68 or
in j with anti-NF-kB. Anti-GAPDH is used for protein normalisation. Data represent mean ± S.E.M. Statistical significance is calculated by student’s t test
referred to vehicle SOD1-G93A mice, * p < 0.05
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expression in SOD1-G93A microglia pre-treated with
wortmannin. We found that wortmannin reversed the
up-regulation of CD68 induced by clemastine (Fig. 6h).
Clemastine treatment affects autophagy in NSC34
SOD1-G93A cultures
Finally, we investigated the in vitro effects of clemastine
on autophagy and SOD1 levels also in a motoneuron-
like cell line. As shown in Fig. 7, in NSC34 SOD1-G93A
cultures, 30-μM clemastine after 6 h remarkably in-
creased LC3II level of about eightfold with respect to
control cells (Fig. 7a), concomitantly with a reduction of
about 40 % in p62 protein content (Fig. 7b). We also ob-
served a significant decrease of p-mTOR in cells treated
with clemastine, whereas the total mTOR remained rela-
tively constant (Fig. 7c). Moreover, in NSC34 SOD1-G93A
cultures, clemastine significantly reduced mutant SOD1
protein, with respect to unstimulated cells (Fig. 7d). Inter-
estingly, after a 24-h treatment with clemastine, we ob-
served a hyper accumulation of LC3II, p62 and p-mTOR
expression in NSC34 SOD1-G93A cells (Fig. 7e–g). This
is consistent with an inhibition of autophagy, as described
for other histamine related compounds when employed
with long incubation times [35, 36]. As shown by western
blot, this arrest of autophagy occurred concomitantly with
an increase in SOD1 level induced by clemastine after
24 h (Fig. 7h).
Discussion
A synergy of different pathological mechanisms such as
motoneuron degeneration, microglia switch from neuro-
protective M2 to deleterious M1 phenotype [37], patho-
logical protein aggregation [38] and aberrant autophagy


































































Ctrl Cle Ctrl Cle
Fig. 5 Clemastine modulates the activation pattern of SOD1-G93A spinal microglia cultures from symptomatic mice. Spinal primary microglia from
SOD1-G93A mice at PND 120 are exposed to clemastine 30 μM for 6 h. a Equal amounts of total lysates are subjected to western blotting with
anti-CD68, anti-ARG-1, anti-CD163, anti-P2X7, anti-P2X4, anti-P2Y12 and anti-GAPDH for protein normalisation. Data represent mean ± S.E.M. of
n = 3 independent experiments. Statistical significance is calculated by student’s t test referred to untreated cells (Ctrl), * p < 0.05. Cells are then
analysed by means of a confocal microscope (scale bar 20 μm) after staining with anti-CD11b (red) and in b with anti-CD68 (green), in c with
anti-ARG-1 (green), in d with anti-CD163 (green) and in e with anti-P2Y12 (green)
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to a drastic acceleration of the disease. The major finding
of this work is that a treatment in SOD1-G93A mice with
the antihistaminergic drug clemastine in presymptomatic
phase (short treatment) affects both neuroinflammatory
parameters (Iba1, CD68, arginase1, CD163, P2X7 and
P2Y12) and autophagic markers (LC3-II and SQSTM1/
p62), moreover decreases SOD1 protein levels and im-
proves motoneuron survival. We thus suppose that modu-
lation of these parameters during the presymptomatic
stage of the disease might contribute to the clemastine-
induced delay of ALS progression and improvement of
pathological features until the end stage.
Conversely, we have also demonstrated that a clemas-
tine treatment up to the end stage of the disease fails in
ameliorating disease progression and instead increases
microgliosis, NF-kB and SOD1 protein levels in the late
phases of the disease. These differences in phenotypic

























































































































Fig. 6 Clemastine decreases SOD1 and stimulates autophagy via mTOR pathway in SOD1-G93A spinal microglia cultures. Spinal primary microglia
from SOD1-G93A mice at PND 120 are exposed to clemastine 30 μM for 6 h. a Equal amounts of treated microglia lysates are subjected to
western blotting with anti-SOD1 and anti-GAPDH. b Cells are analysed by means of a confocal microscope after staining with anti-CD11b (red)
and anti-SOD1 (green) (scale bar 20 μm). c Equal amounts of treated microglia lysates are subjected to western blotting with anti-SQSTM1/p62 or
in d with anti-mTOR and anti-p-mTOR. Anti-GAPDH was used for protein normalisation. e SOD1-G93A microglia are exposed to clemastine 30 μM
and/or bafilomycin-A1 25nM for 6 h, and equal amounts of total lysates are subjected to western blotting with anti-LC3-I/II and anti-GAPDH for
protein normalisation. f Cells are also analysed by means of a confocal microscope after staining with anti-LC3-I/II (red) (scale bar 20 μm). Total
lysates of SOD1-G93A microglia exposed to clemastine and/or wortmannin 100 nM are subjected to western blotting with anti-SOD1 (g) or
anti-CD68 (h). Anti-GAPDH is used for protein normalisation. Data represent mean ± S.E.M. of n = 3 independent experiments. Statistical significance is
calculated by student’s t test referred to untreated cells (Ctrl), * p < 0.05 or to clemastine-treated cells, # p < 0.05
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molecular mechanisms that possess complex and dual
roles in the pathogenesis of ALS, such as neuroin-
flammation and autophagy [37, 40, 41]. While the mild
activation of these parameters by clemastine short treat-
ment could protect motoneuron and improve mice sur-
vival, a persistent stimulation of these same pathways
could be deleterious during the late phases of disease
progression. If we consider that the early stage of ALS is
characterised by neuroinflammation exhibiting neuro-
protective M2 functions that are lost and converted into
M1 toxic actions when disease progression accelerates in
SOD1-G93A mice (approximately around 16–18 weeks)
[37, 41], the efficacy of the short treatment could be
explained by having clemastine sustained neuroinflam-
mation only when it is protective for motor neurons. In
addition, clemastine in the early phase prompts immune
cells to acquire an anti-inflammatory phenotype during
the late phase of the disease, as shown by the decreased
expression of the proinflammatory factor NF-kB, well
known to contribute to immune-mediated motoneuron
death in ALS [31]. Thus, a tight balance in modulating
pathological hallmarks of ALS has to be achieved by
clemastine for ameliorating disease progression. This is
consistent with results obtained on neuroinflammation
and autophagy in ALS, whose modulators can have either
beneficial or detrimental effects [30, 42].
Targeting autophagy in ALS mice has indeed demon-
strated conflicting results since beneficial effects were
reached with both activators as well as inhibitors. For in-






































































































































































Ctrl Cle 24h 
Ctrl Cle 24h
Ctrl Cle 6h
Fig. 7 Autophagy is modulated by clemastine in a time-dependent manner in NSC34 SOD1-G93A motor neuron cells. NSC34 SOD1-G93A motor
neurons are exposed to clemastine 30 μM for 6 h. Equal amounts of treated cells lysates are subjected to western blotting with anti-LC3I/II (a),
anti-SQSTM1/p62 (b), anti-mTOR and anti-p-mTOR (c) or anti-SOD1 (d). Anti-GAPDH is used for protein normalisation. NSC34 SOD1-G93A motor
neurons are exposed to clemastine 30 μM for 24 h. Equal amounts of treated cells lysates are subjected to western blotting with anti-LC3I/II (e),
anti-SQSTM1/p62 (f), anti-mTOR and anti-p-mTOR (g) or anti-SOD1 (h). Anti-GAPDH was used for protein normalisation. Data represent mean ± S.E.M.
of n = 3 independent experiments. Statistical significance is calculated by student’s t test referred to untreated cells (Ctrl), * p < 0.05
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efficacy in ALS models by activating autophagy but, on
the other hand, a recent paper has demonstrated a re-
markable increase in mice life span by down-regulating
autophagy in motor neurons with n-butylidenephthalide
[43]. In addition, rapamycin and lithium both enhancing
autophagy have failed to ameliorate ALS disease [22, 30];
hence, the precise role of autophagy in ALS is still to be
resolved. However, in the case of clemastine, we have
worked within a different experimental paradigm, by hav-
ing interrupted the treatment at the disease symptoms
and shown that clemastine is then effective only when ad-
ministered in the early-stage of the disease (short treat-
ment) where, in addition to increase autophagy, it has
beneficial immune-related actions (M2-like). Thus, we hy-
pothesise that overstimulation of these same pathways
during the long clemastine treatment when the disease
accelerates might conversely activate deleterious M1-like
immune responses and arrest autophagy.
The stimulation of autophagy by clemastine is consist-
ent with the role that antihistamines H1 play in autoph-
agy [44, 45], and with the stimulation of autophagy by
antihistaminergic drugs in ALS [18], in prion-infected
mice [46], in Alzheimer’s disease [16, 47] and in cerebral
ischemia [15], thus suggesting that the efficacy of clem-
astine against ALS might also occur through the autoph-
agic process.
In order to elucidate the clemastine-mediated actions,
we have taken advantage of spinal cord primary micro-
glia from SOD1-G93A symptomatic mice. It is known
that purinergic signalling has a role in microglia [48]. In
particular, P2X7 is involved in microglia-dependent neu-
roprotection [49], P2X4 is a microglia death receptor
[50], and the P2Y12 is known to be enhanced in micro-
glia under alternatively activated M2 conditions [51].
We have shown here that besides activating and polarising
adult microglia towards a M2-like phenotype, clemastine
also increases P2X7 and P2Y12 receptors, while decreas-
ing P2X4 expression, further suggesting that clemastine
prompts SOD1-G93A spinal microglia to acquire a pro-
tective state.
Interplay between inflammatory responses and autoph-
agy in microglia is a common feature of CNS pathologies.
Recently, it was reported that autophagy might influence
inflammation and activation of microglia, as well as
inflammation might promote or inhibit the process of au-
tophagy [52]. In this context, our work has demonstrated
that clemastine can activate autophagy in SOD1-G93A
primary microglia, by increasing LC3-II and decreasing
SQSTM1/p62 and p-mTOR markers, and that microglia
activation by clemastine might depend, at least in part, by
autophagy. This in vitro modulation of autophagy thus
sustains a microglia-mediated effect of clemastine occur-
ring also in vivo, in addition to the concomitant participa-
tion of motor neurons to the autophagic process. Our
results have indeed shown that clemastine modulates
LC3-II, SQSTM1/p62 and mTOR in the NSC34 SOD1-
G93A motoneuron cells in a time-dependent manner, in
parallel with the different effects exerted by short and long
treatment in ALS mice, and thus sustaining at least in part
our hypothesis.
Conclusions
In conclusion, by analysing two pharmacological treat-
ments with clemastine in SOD1-G93A mice, one up to
symptomatic phase and the other up to the end stage of
the disease, we have gained insights into the ameliorat-
ing actions of an antihistaminergic compound in ALS
progression and repositioned clemastine from a drug for
allergic rhinitis to a potential pharmacological compound
for ALS. The beneficial effects on disease progression and
survival found for the short clemastine treatment are in
accordance with previous results obtained for instance
with latrepirdine in SOD1-G93A mice by two different
groups, showing that mice survival was improved only
when the treatment was performed in the presymptomatic
phase and not in the symptomatic phase [18, 53]. By ana-
lysing the implicated mechanisms, we have shown that
proteostasis regulation and neuroinflammation are key
targets of clemastine action. Because retinoids have been
shown to significantly extend SOD1-G93A mice survival
by modulating these same parameters [27, 54], and
current opinion now suggests that mixed approaches
combining drugs with synergic effects might be therapeut-
ically useful, further treatments might consider the use of
retinoids together with clemastine. In addition, given the
sex-dependent neuroprotective effects exerted by drugs in
SOD1 models [22], it will be crucial to test clemastine in
male mice and, finally, to perform dose-dependent trials
in order to prove the clemastine activity in affecting ALS
pathogenesis.
Given the growing interest in studying presymptom-
atic ALS and the identification of always more genes con-
ferring high risk for the disease [55], clemastine might
then represent an exploitable therapeutic approach at least
for the familial forms of ALS.
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